Suppr超能文献

特应性皮炎患儿血清可溶性晚期糖基化终末产物受体水平:一项前瞻性研究。

Serum sRAGE levels in children with atopic dermatitis: a prospective study.

作者信息

Eke-Gungor Hatice, Sagiroglu Bilal, Can-Coskun Zehra Nur, Kocer Derya, Karakukcu Çiğdem

机构信息

Department of Paediatric Allergy and Immunology, University of Health Sciences, Kayseri City Training and Research Hospital, Kayseri, Turkey.

Department of Paediatrics, University of Hitit, Çorum Erol Olçok Training and Research Hospital, Kayseri, Turkey.

出版信息

Postepy Dermatol Alergol. 2023 Dec;40(6):766-771. doi: 10.5114/ada.2023.133585. Epub 2024 Jan 8.

Abstract

INTRODUCTION

Atopic dermatitis (AD) is chronic inflammatory skin disorder. The receptor for advanced glycation end products (RAGE) plays a role in inflammatory reactions. The soluble form of RAGE (sRAGE) acts as a decoy to inhibit interactions of RAGE.

AIM

To determine serum sRAGE levels in children with AD.

MATERIAL AND METHODS

AD diagnosis was made according to Hanifin and Rajka criteria. Disease severity was scored by the scoring atopic dermatitis (SCORAD) index. Skin prick testing (SPT), total immunoglobulin E (Ig E) and eosinophil counts were analysed. The sRAGE levels were determined using ELISA technique.

RESULTS

The children, aged 0.4 to 2.0 years with AD ( = 65) were investigated in two groups according to the presence (AD+/Atopy+ [ = 40]) or absence (AD+/Atopy- [ = 25]) of SPT positivity. The comparisons were made with a healthy control group matched for age and sex. The medians (interquartile range) of sRAGE levels in patient and control groups were 8.43 (1.04-18.37) and 14.09 (6.35-28.64), respectively ( < 0.001). The medians (interquartile range) of sRAGE levels in AD+/Atopy+, AD+/Atopy- and control groups were 8.5 (3.1-17.27), 7.75 (1.04-18.37) and 14.09 (6.35-28.64), respectively ( = 0.004). Correlation analysis failed to reach significance with the disease severity sRAGE levels, total IgE levels and eosinophil counts.

CONCLUSIONS

To our knowledge, this is the first study investigating the association of sRAGE levels with AD and disease severity in childhood. Serum sRAGE levels are decreased in AD but not correlated with disease severity. sRAGE levels may be important in the AD disease process.

摘要

引言

特应性皮炎(AD)是一种慢性炎症性皮肤病。晚期糖基化终产物受体(RAGE)在炎症反应中起作用。可溶性RAGE(sRAGE)作为诱饵抑制RAGE的相互作用。

目的

测定AD患儿血清sRAGE水平。

材料与方法

根据Hanifin和Rajka标准进行AD诊断。采用特应性皮炎评分(SCORAD)指数对疾病严重程度进行评分。分析皮肤点刺试验(SPT)、总免疫球蛋白E(IgE)和嗜酸性粒细胞计数。使用酶联免疫吸附测定(ELISA)技术测定sRAGE水平。

结果

对年龄在0.4至2.0岁的AD患儿(n = 65),根据SPT阳性(AD+/特应性体质+ [n = 40])或阴性(AD+/特应性体质- [n = 25])分为两组进行研究。与年龄和性别匹配的健康对照组进行比较。患者组和对照组sRAGE水平的中位数(四分位间距)分别为8.43(1.04 - 18.37)和14.09(6.35 - 28.64)(P < 0.001)。AD+/特应性体质+组、AD+/特应性体质-组和对照组sRAGE水平的中位数(四分位间距)分别为8.5(3.1 - 17.27)、7.75(1.04 - 18.37)和14.09(6.35 - 28.64)(P = 0.004)。相关性分析显示,sRAGE水平与疾病严重程度、总IgE水平和嗜酸性粒细胞计数之间无显著相关性。

结论

据我们所知,这是第一项研究儿童sRAGE水平与AD及疾病严重程度之间关联的研究。AD患儿血清sRAGE水平降低,但与疾病严重程度无关。sRAGE水平可能在AD疾病进程中具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3d07/10809839/97241e5c03c5/PDIA-40-52003-g001.jpg

相似文献

1
Serum sRAGE levels in children with atopic dermatitis: a prospective study.
Postepy Dermatol Alergol. 2023 Dec;40(6):766-771. doi: 10.5114/ada.2023.133585. Epub 2024 Jan 8.
2
The plasma gelsolin levels in atopic dermatitis: Effect of atopy and disease severity.
Allergol Immunopathol (Madr). 2016 May-Jun;44(3):221-5. doi: 10.1016/j.aller.2015.05.005. Epub 2015 Aug 28.
3
Factors that predict disease severity in atopic dermatitis: The role of serum basal tryptase.
Allergy Asthma Proc. 2018 Sep 1;39(5):371-376. doi: 10.2500/aap.2018.39.4158.
5
The role of cow milk allergy in increasing the severity of atopic dermatitis.
Immunol Invest. 2004 Feb;33(1):69-79. doi: 10.1081/imm-120027686.
6
Assessment of IL-31 levels and disease severity in children with atopic dermatitis.
Allergol Immunopathol (Madr). 2018 Jul-Aug;46(4):322-325. doi: 10.1016/j.aller.2017.10.005. Epub 2018 Mar 17.
8
Evaluation of Oxidant-Antioxidant Balance in Children with Atopic Dermatitis: A Case-Control Study.
Am J Clin Dermatol. 2016 Oct;17(5):527-537. doi: 10.1007/s40257-016-0210-8.

引用本文的文献

2
Pathological role of RAGE underlying progression of various diseases: its potential as biomarker and therapeutic target.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):3467-3487. doi: 10.1007/s00210-024-03595-6. Epub 2024 Nov 26.

本文引用的文献

1
Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases.
Molecules. 2022 Aug 2;27(15):4922. doi: 10.3390/molecules27154922.
2
Soluble receptor for advanced glycation end products (sRAGE) and asthma: Mendelian randomisation study.
Pediatr Allergy Immunol. 2021 Jul;32(5):1100-1103. doi: 10.1111/pai.13478. Epub 2021 Mar 5.
3
Involvement of RAGE and Oxidative Stress in Inflammatory and Infectious Skin Diseases.
Antioxidants (Basel). 2021 Jan 9;10(1):82. doi: 10.3390/antiox10010082.
5
The axis of the receptor for advanced glycation endproducts in asthma and allergic airway disease.
Allergy. 2021 May;76(5):1350-1366. doi: 10.1111/all.14600. Epub 2020 Oct 9.
7
Japanese guidelines for atopic dermatitis 2020.
Allergol Int. 2020 Jul;69(3):356-369. doi: 10.1016/j.alit.2020.02.006. Epub 2020 Apr 4.
8
Serum soluble receptor for advanced glycation end-products during acute bronchiolitis in infant: Prospective study in 93 cases.
Pediatr Pulmonol. 2018 Oct;53(10):1429-1435. doi: 10.1002/ppul.24141. Epub 2018 Aug 16.
9
Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases?
Mol Cell Biochem. 2019 Jan;451(1-2):139-144. doi: 10.1007/s11010-018-3400-2. Epub 2018 Jun 30.
10
The effects of advanced glycation end products (AGEs) on dermal wound healing and scar formation: a systematic review.
Scars Burn Heal. 2016 Dec 5;2:2059513116676828. doi: 10.1177/2059513116676828. eCollection 2016 Jan-Dec.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验